Quest Partners LLC Grows Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Quest Partners LLC lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 885.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,947 shares of the company's stock after purchasing an additional 21,516 shares during the period. Quest Partners LLC's holdings in Protagonist Therapeutics were worth $1,078,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Protagonist Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company's stock worth $95,000 after purchasing an additional 379 shares during the period. GAMMA Investing LLC raised its holdings in Protagonist Therapeutics by 749.2% during the third quarter. GAMMA Investing LLC now owns 552 shares of the company's stock valued at $25,000 after acquiring an additional 487 shares during the period. Exchange Traded Concepts LLC purchased a new position in shares of Protagonist Therapeutics in the third quarter valued at about $43,000. CWM LLC boosted its stake in shares of Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company's stock worth $57,000 after acquiring an additional 1,147 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of Protagonist Therapeutics by 9.2% during the first quarter. ProShare Advisors LLC now owns 14,345 shares of the company's stock worth $415,000 after purchasing an additional 1,206 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Trading Up 3.0 %

Shares of NASDAQ PTGX traded up $1.20 during mid-day trading on Thursday, reaching $41.85. The company had a trading volume of 246,172 shares, compared to its average volume of 743,536. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of 16.18 and a beta of 2.17. The business's 50-day moving average is $45.34 and its 200-day moving average is $39.00. Protagonist Therapeutics, Inc. has a 52 week low of $16.80 and a 52 week high of $48.89.

Analyst Ratings Changes

PTGX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Protagonist Therapeutics from $39.00 to $48.00 and gave the company an "overweight" rating in a report on Thursday, July 25th. StockNews.com raised Protagonist Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday. BTIG Research boosted their price objective on Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a "buy" rating in a research note on Wednesday, July 24th. Finally, Truist Financial started coverage on Protagonist Therapeutics in a research note on Monday, September 9th. They issued a "buy" rating and a $60.00 price objective for the company. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Protagonist Therapeutics presently has an average rating of "Buy" and an average target price of $53.57.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 8,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the sale, the director now owns 12,000 shares of the company's stock, valued at approximately $540,000. The trade was a 40.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Asif Ali sold 14,203 shares of the firm's stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total transaction of $631,891.47. Following the transaction, the chief financial officer now directly owns 34,960 shares of the company's stock, valued at $1,555,370.40. This represents a 28.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,109 shares of company stock valued at $1,069,999. Company insiders own 5.40% of the company's stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.